Performance of featured public companies this past week.
Cybin ($CYBN)partnered with Clinilabs to advance their proprietary deuterated psilocybin analog, CYB003, in a Phase I/IIa clinical trial. CYB003 will be the first psilocybin analog to be evaluated in Phase I/IIa development for the treatment of major depressive disorder.Press Release
Wesana Health Holdings ($WESA | $WSNAF) announced that following the completion of a successful Pre-IND meeting with the FDA, Wesana began exploring the opportunity to expand their lead indication for SANA-013 to major depressive disorder. Wesana is also exploring the opportunity to accelerate the development of SANA-013 by initiating a Phase Ib/IIa human study for MDD. Press Release
Psyence Group ($PSYG | $PSYGF) entered into an exclusive licensing agreement with Filament Health. Filament will license their proprietary botanical drug candidate PEX010 to Psyence Group for use in their upcoming clinical trials focused on palliative care.Press Release
Psyched Wellness ($PSYC | $PSYCF) announced that their CEO, Director, and Co-Founder, Jeffrey Stevens, has increased his position in Psyched Wellness by 321,000 shares, further reinforcing his support and confidence in the company. Press Release
Wellbeing Digital Sciences ($MEDI | $KONEF) provided commercial updates for their wholly owned subsidiary, KGK Science and signed a memorandum of understanding with Pathway Health. Details
NeonMind Biosciences ($NEON | $NMDBD) advanced their strategy to enhance access to treatments at their specialty mental health clinics with Impetus Digital and Thrive Health in preparation of opening their inaugural clinic in Ontario. Details
Revitalist Lifestyle And Wellness ($CALM | $RVLWF) closed an initial tranche of their private placement offering for total gross proceeds of $3.8M. Revitalist CEO, Kathryn Walker, invested $2.3M into the offering further reinforcing her belief in the company. Press Release